We're locking in a 220% gain on a core holding to guard against an earnings letdown

Novo Nordisk significantly slashed its 2025 sales growth outlook to 8-14% from 13-21%, causing its shares to plummet over 20% due to lower U.S. expectations for its GLP-1 drugs, citing compounded alternatives, slower market expansion, and competition. In response, Eli Lilly (LLY) shares fell in sympathy, prompting Jim Cramer's Charitable Trust to sell LLY shares and lock in a 220% profit. The Trust cited broader market uncertainties regarding GLP-1 expansion and compounded drug impact, despite LLY's competitive advantages, as reasons for reducing exposure ahead of LLY's earnings.

Analysis

A significant downward revision in Novo Nordisk's 2025 sales growth outlook to a range of 8-14% from 13-21% has triggered a sharp, over 20% decline in its share price and created negative sentiment across the GLP-1 market. This guidance cut, attributed to slower-than-expected market expansion, competition, and the use of compounded drugs in the U.S., has directly impacted Eli Lilly, whose shares have fallen in sympathy. The situation presents a mixed signal for Eli Lilly investors. While Novo Nordisk's mention of heightened competition suggests Eli Lilly is successfully gaining market share, the concerns over a decelerating overall market and the persistence of compounded alternatives represent potential industry-wide headwinds. Eli Lilly is positioned with distinct advantages, including what are described as superior GLP-1 products, a prospective oral medication, and stronger manufacturing capacity, contrasting with Novo Nordisk's recent supply constraints and management changes. Nevertheless, the uncertainty introduced by its primary competitor's outlook, particularly ahead of Lilly's own earnings report on August 7, is substantial enough to warrant a de-risking strategy, as demonstrated by the decision to realize a 220% gain on a portion of the position.

Key Decisions for Investors

• Investors should consider trimming exposure to Eli Lilly to lock in substantial profits and reduce risk ahead of its August 7th earnings report, given the market-wide uncertainty created by Novo Nordisk's guidance.
• Closely scrutinize Eli Lilly's upcoming earnings call for management's commentary on the overall GLP-1 market expansion rate and the impact of compounded drugs to determine if the headwinds are industry-wide or specific to Novo Nordisk.
• For those with a long-term thesis, any excessive weakness in Eli Lilly's stock following this news could be viewed as a potential opportunity, contingent on the company demonstrating continued market share gains and operational superiority over its rival.